Correction: p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8⁺ T-cell Responses

In this article (Clin Cancer Res 2014;20:4459–70), which was published in the September 1, 2015, issue of Clinical Cancer Research (1), the source for the vaccine was not included in the published article. The Acknowledgments section, with the vaccine source, should read as follows: “The authors thank the following City of Hope staff and departments: The Investigational Drug Service, David Hsu, Yasmine Shad, and Larry Couture (Centre Biomedicine and Genetics), Richard Ermel (Director of Animal Resources), The Office of IND Development and Regulatory Affairs, Mario Dimacali (Clinical Research Associate), and Michael A Friedman (CEO Emeritus of City of Hope). The authors also thank Bernard Moss (NIH) for allowing access to 1974-MVA and the National Institute of Allergy and Infectious Diseases for agreeing to the transfer for clinical use. They also thank Dimitri Gabriolvich and Scott Antonia (H. Lee Moffitt Cancer Center, University of South Florida, Tampa FL) for their kind gift of Advexin. The authors wish to acknowledge a gift of purified rabbit anti-vaccinia sera that was manufactured by Quality Biological Inc. (Gaithersburg, MD) under contract No. HHSN272201100023C issued by the Vaccine Research Program, Division of AIDS, NIAID.” The authors regret this error.